H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nuvation Bio (NUVBResearch Report) today and set a price target of $4.50. The company’s shares closed last Friday at $2.09.

According to TipRanks, Burns is an analyst with an average return of -22.7% and a 22.60% success rate. Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, MacroGenics, and BioNTech SE.

Nuvation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $10.45 and a one-year low of $1.92. Currently, Nuvation Bio has an average volume of 616.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More